An interventional study of Adagio AF Cryoablation System (iCLAS™) in Persistent Atrial Fibrillation, sponsored by Adagio Medical. Completed at 21 sites in 4 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-08-06.
Sponsored by Adagio Medical · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 993 studies in Atrial Fibrillation with a site in United States — 160 open to participants now, 220 under way, 15 of them phase 3. Atrial Fibrillation · United States.
Among the 993 studies in Atrial Fibrillation with a site in United States, this one is the 249th largest by enrollment of the 679 interventional ones that give a count, is one of 58 that started in 2019, is one of 405 with no phase, and was the 605th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →160 of the 993 studies in Atrial Fibrillation with a site in United States are open now. Recruiting first, the newest first:
Kardium Inc. · Sites in United States
Ages 18+
Mayo Clinic · Sites in United States
Ages 40+
Boston Scientific Corporation · Sites in United States
Ages 18+
Bayer · Sites in United States, Belgium, Bulgaria and 5 more countries
Ages 18–85
Texas Cardiac Arrhythmia Research Foundation · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
993 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 30 · Phase 2 71 · Phase 3 107 · Phase 4 87
First in 1989; this study’s year is marked. 58 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 215 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 127 across the 679 interventional studies, 200 across the 308 observational. Of the 675 that completed or were terminated, 304 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
349 of 993 have an industry lead sponsor. The 10 most frequent:
Adagio Medical is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Adagio Medical has 4 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
75 of the studies in Atrial Fibrillation with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06376916Phase 3Wake Forest University Health SciencesComparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR | 2026-12 |
| NCT05757869Phase 3Janssen Research & Development, LLCA Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation | 2026-12-08 |
| NCT03907046Phase 3Yale UniversityAnticoagulation in ICH Survivors for Stroke Prevention and Recovery | 2027-04 |
| NCT05174052Phase 3University of OklahomaDapagliflozin in Patients With Atrial Fibrillation (DAPA-AF) | 2027-04 |
| NCT02750319Phase 3Memorial Sloan Kettering Cancer CenterAmiodarone and N-Acetylcysteine or Amiodarone Alone for Preventing Atrial Fibrillation After Thoracic Surgery | 2027-04 |
Add all 75 to your calendar (.ics) → With an account.
Among the 993 studies in Atrial Fibrillation with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical study to evaluate the safety and efficacy of the Adagio AF Cryoablation System (iCLAS™) in the ablation treatment of symptomatic, persistent atrial fibrillation (PsAF). Data will be used to support a pre-market application (PMA)
A staged pre-market, single-arm, clinical study designed to collect acute and long-term safety and efficacy data for the Adagio AF Cryoablation System (iCLAS™). Patient population will consist of symptomatic, persistent AF subjects completing a de novo ablation procedure. Enrollment will be 200 subjects at up to 20 global investigational sites. Subjects will receive an ablation with the ultra-low cryoablation device. Follow-up will include assessment at one, three, six, and twelve months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
IC1 Male or female between the ages of 18 and 80 years
IC2 Currently scheduled for an ablation of symptomatic, PsAF defined as continuous AF that is sustained > 7-days and ≤ 12 months and documented by the following: a. Physician's note indicating continuous AF > 7 days and ≤ 12 months, AND b. One of the following: i. 24-hour Holter within 180 days of enrollment showing continuous AF, OR ii. Two from any forms of rhythm monitoring (e.g., 12-lead ECGs or single lead ECGs) completed ≥ 7 days apart within 180 days of enrollment.
IC3 to at least one class I or III AAD. (Refractory defined as not effective, not tolerated or not desired)
IC4 Willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study
IC5 Willingness and ability to give an
EXCLUSION CRITERIA
EC 1 In the opinion of the Investigator, any known to an atrial ablation, TEE, or anticoagulation. Including, but not limited to, the identification of any atrial thrombus or evidence of sepsis
EC 2 Any duration of continuous AF lasting longer than 12-months
EC 3 History of previous left atrial ablation or surgical treatment for AF/AFL/AT
EC 4 Atrial fibrillation secondary to electrolyte imbalance, active thyroid disease, or any other reversible or non-cardiac cause
EC 5 Structural heart disease as described below:
EC 6 > 40
EC 7 Any previous history of cryoglobulinemia
EC 8 History of blood clotting or bleeding disease
EC 9 History of severe requiring use in the previous 12-months
EC 10 History of severe sleep apnea (AHI > 30) not currently treated with a CPAP machine or other mechanical device
EC 11 Any prior history of documented cerebral infarct including recent (within one year) or systemic embolism (excluding a post-operative DVT)
EC 12 Any prior history or current evidence of hemidiaphragmatic paralysis
EC 13 Pregnant or lactating (current or anticipated during study follow-up)
EC 14 Current enrollment in any other study protocol where testing or results from that study may interfere with the procedure or outcome measurements for this study
EC 15 Any other condition that, in the judgment of the investigator, makes the patient a poor candidate for this procedure, the study or compliance with the protocol (includes vulnerable patient population, mental illness, addictive disease, terminal illness with a of less than two years, extensive travel away from the research center, COVID-19 related concerns)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ablation of the left and right atrium with the Adagio Medical iCLAS System
Device: Adagio AF Cryoablation System (iCLAS™)
Endovascular ablation of the left and right atrium
Analysis of the Proportion of Subjects Who Are Free From Device/Procedure Related Major Adverse Events (MAEs) That Occur Following the Cryoablation Procedure
Analysis of the proportion of subjects who are free from device/procedure related Major Adverse Events (MAEs) that occur following the cryoablation procedure. MAEs include any of the following: * Death * Myocardial infarction * Cardiac perforation/pericardial tamponade * Cerebral infarct or systemic embolism * Major bleeding requiring transfusion of blood products * Mitral or tricuspid valve damage * Symptomatic pulmonary vein stenosis * Severe (≥ 70%) pulmonary vein stenosis * Permanent phrenic nerve injury * Access site complications requiring pharmacological or surgical intervention * Atrio-esophageal fistula * Pericarditis * Heart block requiring a permanent pacemaker * Vagal nerve injury with GI dysmotility * Other serious adverse device effects (SADEs), including TIAs, adjudicated by an independent Clinical Events Committee (CEC) as "probably or definitely related" to the Adagio System
Time frame: 12-months
Analysis of the Proportion of Subjects Receiving a Single Cryoablation Who Are Free From Any Documented Left Atrial Arrhythmia (AF/AFL/AT) Following the Blanking Period Lasting Longer Than 30 Seconds on a Continuous 24-hour ECG Recording (Holter Monitor).
Analysis of the proportion of subjects receiving a single cryoablation who are free from any documented left atrial arrhythmia (AF/AFL/AT) following the Blanking Period lasting longer than 30 seconds on a continuous 24-hour ECG recording (Holter monitor). The primary effectiveness endpoint will be based on a centralized core lab interpretation of the recordings used in the endpoint analysis.
Time frame: 12-months
Analysis of the Proportion of Subjects With Acute Procedural (Ablation) Success
Percentage of patients with documentation of pulmonary vein isolation (LSPV, LIPV, RSPV, RIPV) and posterior wall isolation (PWI) and cavo-tricuspid isthmus (CTI) bidirectional block (BDB) following the last ablation of PV, PW, and CTI.
Time frame: 20-minutes following last ablation
215 patients were enrolled
| Milestone | iCLAS Ablation |
|---|---|
| Started | 189 |
| Completed | 175 |
| Not completed | 14 |
Analysis of the proportion of subjects who are free from device/procedure related Major Adverse Events (MAEs) that occur following the cryoablation procedure. MAEs include any of the following: * Death * Myocardial infarction * Cardiac perforation/pericardial tamponade * Cerebral infarct or systemic embolism * Major bleeding requiring transfusion of blood products * Mitral or tricuspid valve damage * Symptomatic pulmonary vein stenosis * Severe (≥ 70%) pulmonary vein stenosis * Permanent phrenic nerve injury * Access site complications requiring pharmacological or surgical intervention * Atrio-esophageal fistula * Pericarditis * Heart block requiring a permanent pacemaker * Vagal nerve injury with GI dysmotility * Other serious adverse device effects (SADEs), including TIAs, adjudicated by an independent Clinical Events Committee (CEC) as "probably or definitely related" to the Adagio System
| Participants | Safety Cohort |
|---|---|
| Analysis of the Proportion of Subjects Who Are Free From Device/Procedure Related Major Adverse Events (MAEs) That Occur Following the Cryoablation Procedure | 3 |
Analysis of the proportion of subjects receiving a single cryoablation who are free from any documented left atrial arrhythmia (AF/AFL/AT) following the Blanking Period lasting longer than 30 seconds on a continuous 24-hour ECG recording (Holter monitor). The primary effectiveness endpoint will be based on a centralized core lab interpretation of the recordings used in the endpoint analysis.
| Participants | Modified Intention-to-treat (mITT) Population |
|---|---|
| Analysis of the Proportion of Subjects Receiving a Single Cryoablation Who Are Free From Any Documented Left Atrial Arrhythmia (AF/AFL/AT) Following the Blanking Period Lasting Longer Than 30 Seconds on a Continuous 24-hour ECG Recording (Holter Monitor). | 97 |
Percentage of patients with documentation of pulmonary vein isolation (LSPV, LIPV, RSPV, RIPV) and posterior wall isolation (PWI) and cavo-tricuspid isthmus (CTI) bidirectional block (BDB) following the last ablation of PV, PW, and CTI.
| percentage of participants | Modified Intention-to-treat (mITT) Population |
|---|---|
| PVI- LSPV Achieved | 94.2 |
| PVI- LIPV Achieved | 94.9 |
| PVI- RSPV Achieved | 97.8 |
| PVI- RIPV Achieved | 97.1 |
| PWI | 96.4 |
| CTI BDB Achieved | 87.2 |
Collected over 12-month. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| iCLAS Ablation | 3/189 (1.6%) | 10/189 (5.3%) | 14/189 (7.4%) |
| Event | iCLAS Ablation |
|---|---|
| Vascular access site complicationsVascular disorders | 3/189 |
| Phrenic nerve injuryInjury, poisoning and procedural complications | 2/189 |
| Esophageal injuryGastrointestinal disorders | 2/189 |
| Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders | 1/189 |
| Cerebral infarct or systemic embolismNervous system disorders | 1/189 |
| Vascular access site bleedingInjury, poisoning and procedural complications | 1/189 |
| Event | iCLAS Ablation |
|---|---|
| Vascular access site complicationsVascular disorders | 7/189 |
| Phrenic nerve injuryInjury, poisoning and procedural complications | 7/189 |
| Age, Continuous(years) | iCLAS Ablation |
|---|---|
| Mean | 65.5 ± 8.4 |
| Sex: Female, Male(Participants) | iCLAS Ablation |
|---|---|
| Female | 50 |
| Male | 139 |
| Race and Ethnicity Not Collected(Participants) | iCLAS Ablation |
|---|
| Left Ventricular Ejection Fraction (LVEF)(%) | iCLAS Ablation |
|---|---|
| Mean | 56 ± 7.4 |
Plan to share: No
Ran from Dec 2019 to primary completion in Aug 2023, 44 months.
Results were first posted in Aug 2026, 2 years 11 months after primary completion.
Of 255 industry-sponsored interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 36. This study's 44 months is above that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adagio Medical